Cargando…
[18F]FDDNP performed better than [18F] Florbetapir to distinguish transthyretin cardiac amyloidosis (TTR-CA) patients from healthy controls: an ex vivo study
Autores principales: | Dupont, Anne-Claire, Guilloteau, Denis, Ben-Azzouna, Rana, Bidault, Rudy, Algalarrondo, Vincent, Slama, Michel, Arlicot, Nicolas, Le Guludec, Dominique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642089/ http://dx.doi.org/10.1186/1750-1172-10-S1-P38 |
Ejemplares similares
-
Pilot Study of F18-Florbetapir in the Early Evaluation of Cardiac Amyloidosis
por: Sperry, Brett W., et al.
Publicado: (2021) -
Radiation dosimetry of florbetapir F 18
por: Joshi, Abhinay D, et al.
Publicado: (2014) -
Evaluation of Tracer Kinetic Models for Analysis of [(18)F]FDDNP Studies
por: Yaqub, Maqsood, et al.
Publicado: (2009) -
Extracardiac (18)F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds
por: Wagner, T., et al.
Publicado: (2018) -
Dual-phase [18F]florbetapir in frontotemporal dementia
por: Asghar, Michael, et al.
Publicado: (2018)